TCN 032

Drug Profile

TCN 032

Alternative Names: Anti-influenza monoclonal antibody - Theraclone Sciences; IgG monoclonal antibody - Theraclone Sciences; TCN-032

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theraclone Sciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Influenza A virus M2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza A virus infections

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in USA (IV, Infusion)
  • 03 Aug 2015 Phase II development is ongoing in United Kingdom, and phase I development is ongoing in USA
  • 10 Sep 2013 TCN 032 is available for licensing in World (excluding Japan) - www.theraclone-sciences.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top